{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:42:20Z","timestamp":1791229340446,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2006,4,1]],"date-time":"2006-04-01T00:00:00Z","timestamp":1143849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2006,4]]},"DOI":"10.1016\/j.intimp.2005.11.017","type":"journal-article","created":{"date-parts":[[2005,12,15]],"date-time":"2005-12-15T18:00:20Z","timestamp":1134669620000},"page":"579-591","source":"Crossref","is-referenced-by-count":43,"title":["Use of IGIV in the treatment of atopic dermatitis, urticaria, scleromyxedema, pyoderma gangrenosum, psoriasis, and pretibial myxedema"],"prefix":"10.1016","volume":"6","author":[{"given":"Stephen","family":"Jolles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2005.11.017_bib1","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0140-6736(81)92400-4","article-title":"High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood","volume":"1","author":"Imbach","year":"1981","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2005.11.017_bib2","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/archderm.134.1.80","article-title":"Dermatological uses of high-dose intravenous immunoglobulin","volume":"134","author":"Jolles","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.intimp.2005.11.017_bib3","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1046\/j.1365-2567.2002.01545.x","article-title":"Immunomodulatory action of intravenous immunoglobulin","volume":"107","author":"Sewell","year":"2002","journal-title":"Immunology"},{"key":"10.1016\/j.intimp.2005.11.017_bib4","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1136\/bmj.316.7135.936","article-title":"Management of aseptic meningitis secondary to intravenous immunoglobulin","volume":"316","author":"Jolles","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.intimp.2005.11.017_bib5","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2165\/00002018-199309040-00003","article-title":"Adverse effects of intravenous immunoglobulin","volume":"9","author":"Misbah","year":"1993","journal-title":"Drug Saf"},{"key":"10.1016\/j.intimp.2005.11.017_bib6","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/adc.70.4.335","article-title":"High-dose gammaglobulin treatment for atopic dermatitis","volume":"70","author":"Kimata","year":"1994","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.intimp.2005.11.017_bib7","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1046\/j.1365-2133.2000.03377.x","article-title":"The treatment of atopic dermatitis with adjunctive high-dose intravenous immunoglobulin: a report of three patients and review of the literature","volume":"142","author":"Jolles","year":"2000","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.intimp.2005.11.017_bib8","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1081-1206(10)62802-5","article-title":"High-dose intravenous immunoglobulin in atopic dermatitis and hyper-IgE syndrome","volume":"81","author":"Wakim","year":"1998","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.intimp.2005.11.017_bib9","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S1081-1206(10)63384-4","article-title":"Eczema and thrombocytopenia in an 8-month-old infant boy","volume":"78","author":"Weiss","year":"1997","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.intimp.2005.11.017_bib10","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S1081-1206(10)62785-8","article-title":"Changes of serum levels of interleukin-2, intercellular adhesion molecule-1, endothelial leukocyte adhesion molecule-1 and Th1 and Th2 cell in severe atopic dermatitis after intravenous immunoglobulin therapy","volume":"84","author":"Huang","year":"2000","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.intimp.2005.11.017_bib11","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1046\/j.1365-2133.2002.04833.x","article-title":"A randomized controlled evaluator-blinded trial of intravenous immunoglobulin in adults with severe atopic dermatitis","volume":"147","author":"Paul","year":"2002","journal-title":"Br J Dermatol"},{"issue":"Suppl 1","key":"10.1016\/j.intimp.2005.11.017_bib12","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/cei.1996.104.s1.61","article-title":"Intravenous immune globulin: an alternative therapy in steroid-dependent allergic diseases","volume":"104","author":"Gelfand","year":"1996","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.intimp.2005.11.017_bib13","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1080\/00015550310020549","article-title":"Adjunctive high-dose intravenous immunoglobulin treatment for resistant atopic dermatitis: efficacy and effects on intracellular cytokine levels and CD4 counts","volume":"83","author":"Jolles","year":"2003","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.intimp.2005.11.017_bib14","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3346\/jkms.1999.14.1.63","article-title":"Intravenous immune globulin (i.v.IG) therapy in steroid-resistant atopic dermatitis","volume":"14","author":"Noh","year":"1999","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.intimp.2005.11.017_bib15","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/jnnp.63.1.106","article-title":"The use of self infused intravenous immunoglobulin home therapy in the treatment of acquired chronic demyelinating neuropathies","volume":"63","author":"Sewell","year":"1997","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.intimp.2005.11.017_bib16","series-title":"Intravenous immunoglobulin in dermatology","first-page":"33","article-title":"Chronic urticaria","author":"O'Donnell","year":"2003"},{"key":"10.1016\/j.intimp.2005.11.017_bib17","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1365-2133.1997.tb14895.x","article-title":"The impact of chronic urticaria on the quality of life","volume":"136","author":"O'Donnell","year":"1997","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.intimp.2005.11.017_bib18","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJM199306033282204","article-title":"Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria","volume":"328","author":"Hide","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.intimp.2005.11.017_bib19","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1111\/1523-1747.ep12338544","article-title":"Dermal mast cell activation by autoantibodies against the high affinity IgE receptor in chronic urticaria","volume":"106","author":"Niimi","year":"1996","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.intimp.2005.11.017_bib20","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJM199406093302307","article-title":"The pharmacology and use of H1-receptor-antagonist drugs","volume":"330","author":"Simons","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.intimp.2005.11.017_bib21","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1046\/j.1365-2133.1998.02175.x","article-title":"The characteristics of urticaria in 390 patients","volume":"138","author":"Humphreys","year":"1998","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.intimp.2005.11.017_bib22","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1046\/j.1365-2133.2000.03664.x","article-title":"Randomized double-blind study of cyclosporin in chronic \u2018idiopathic\u2019 urticaria","volume":"143","author":"Grattan","year":"2000","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.intimp.2005.11.017_bib23","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1046\/j.1365-2133.1998.02033.x","article-title":"Intravenous immunoglobulin in autoimmune chronic urticaria","volume":"138","author":"O'Donnell","year":"1998","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.intimp.2005.11.017_bib24","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/000155500750043131","article-title":"The effectiveness of low-dose intravenous immunoglobulin in chronic urticaria","volume":"80","author":"Kroiss","year":"2000","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.intimp.2005.11.017_bib25","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1034\/j.1398-9995.2000.00829.x","article-title":"Are IVIG for chronic unremitting urticaria effective","volume":"55","author":"Asero","year":"2000","journal-title":"Allergy"},{"key":"10.1016\/j.intimp.2005.11.017_bib26","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1046\/j.1365-2133.2003.05486.x","article-title":"Effect of high-dose intravenous immunoglobulin in delayed pressure urticaria","volume":"149","author":"Dawn","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.intimp.2005.11.017_bib27","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0151-9638(04)93546-6","article-title":"Treatment of solar urticaria by intravenous immunoglobulins and PUVA therapy","volume":"131","author":"Darras","year":"2004","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.intimp.2005.11.017_bib28","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0190-9622(95)90007-1","article-title":"Scleromyxedema","volume":"33","author":"Dinneen","year":"1995","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.intimp.2005.11.017_bib29","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1365-2133.1973.tb07515.x","article-title":"Scleromyxoedema (lichen myxoedematosus) associated with a paraprotein, IgG 1 of type kappa","volume":"88","author":"Lai a Fat","year":"1973","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.intimp.2005.11.017_bib30","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1016\/j.jaad.2004.03.023","article-title":"A complete and durable clinical response to high-dose dexamethasone in a patient with scleromyxedema","volume":"51","author":"Horn","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.intimp.2005.11.017_bib31","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jaad.2004.01.058","article-title":"Treatment of recalcitrant scleromyxedema with thalidomide in 3 patients","volume":"51","author":"Sansbury","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.intimp.2005.11.017_bib32","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1136\/ard.61.1.59","article-title":"Intravenous immunoglobulins control scleromyxoedema","volume":"61","author":"Righi","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.intimp.2005.11.017_bib33","series-title":"Treatment of neurological disorders with intravenous immunoglobulins","first-page":"44","article-title":"Chronic inflammatory demyelinating polyneuropathy","author":"van Doorn","year":"2000"},{"key":"10.1016\/j.intimp.2005.11.017_bib34","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1067\/mjd.2000.104001","article-title":"Scleromyxedema: response to high-dose intravenous immunoglobulin (hdIVIg)","volume":"43","author":"Lister","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.intimp.2005.11.017_bib35","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1365-2230.2004.01518.x","article-title":"Successful treatment of scleromyxoedema with high-dose intravenous immunoglobulin","volume":"29","author":"Karim","year":"2004","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.intimp.2005.11.017_bib36","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1191\/1352458504ms987cr","article-title":"Scleromyxedema in a patient with multiple sclerosis and monoclonal gammopathy on interferon beta-1a","volume":"10","author":"Kumar","year":"2004","journal-title":"Mult Scler"},{"key":"10.1016\/j.intimp.2005.11.017_bib37","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1365-2133.2003.05682.x","article-title":"Scleromyxoedema: treatment of cutaneous and systemic manifestations with high-dose intravenous immunoglobulin","volume":"149","author":"Kulczycki","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.intimp.2005.11.017_bib38","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/00003226-200301000-00021","article-title":"Annular crystalline keratopathy in association with immunoglobulin therapy for pyoderma gangrenosum","volume":"22","author":"Budde","year":"2003","journal-title":"Cornea"},{"key":"10.1016\/j.intimp.2005.11.017_bib39","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1067\/mjd.2003.172","article-title":"Superficial granulomatous pyoderma treated with intravenous immunoglobulin","volume":"48","author":"Dobson","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.intimp.2005.11.017_bib40","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0190-9622(98)70052-0","article-title":"Successful treatment of pyoderma gangrenosum with intravenous human immunoglobulin","volume":"39","author":"Dirschka","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.intimp.2005.11.017_bib41","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/095466301750163527","article-title":"The use of high-dose immunoglobulin in the treatment of pyoderma gangrenosum","volume":"12","author":"Hagman","year":"2001","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.intimp.2005.11.017_bib42","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s001050051003","article-title":"Post-traumatic pyoderma gangrenosum: combination therapy with intravenous immunoglobulins and systemic corticosteroids","volume":"50","author":"Gleichmann","year":"1999","journal-title":"Hautarzt"},{"key":"10.1016\/j.intimp.2005.11.017_bib43","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/0190-9622(95)90218-X","article-title":"Efficacy of human intravenous immune globulin in pyoderma gangrenosum","volume":"32","author":"Gupta","year":"1995","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.intimp.2005.11.017_bib44","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/archderm.1958.01560040036006","article-title":"Pyoderma gangrenosum associated with hypogammaglobulinemia","volume":"77","author":"Bloom","year":"1958","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.intimp.2005.11.017_bib45","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/jid.1955.40","article-title":"Hypogammaglobulinemia in pyoderma gangrenosum","volume":"24","author":"Marcussen","year":"1955","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.intimp.2005.11.017_bib46","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1046\/j.1365-2133.2002.04753.x","article-title":"Psoriasis: response to high-dose intravenous immunoglobulin in three patients","volume":"147","author":"Gurmin","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.intimp.2005.11.017_bib47","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1006\/clin.1994.1059","article-title":"TSH and TSH receptor antibody-binding sites in fibroblasts of pretibial myxedema are related to the extracellular domain of entire TSH receptor","volume":"71","author":"Chang","year":"1994","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.intimp.2005.11.017_bib48","doi-asserted-by":"crossref","first-page":"8904","DOI":"10.1073\/pnas.95.15.8904","article-title":"Leukoregulin induction of protein expression in human orbital fibroblasts: evidence for anatomical site-restricted cytokine-target cell interactions","volume":"95","author":"Young","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.intimp.2005.11.017_bib49","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1089\/thy.1994.4.399","article-title":"Pretibial myxedema and high-dose intravenous immunoglobulin treatment","volume":"4","author":"Antonelli","year":"1994","journal-title":"Thyroid"},{"key":"10.1016\/j.intimp.2005.11.017_bib50","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1046\/j.1365-2230.2003.01232_3.x","article-title":"Lack of response of elephantiasic pretibial myxoedema to treatment with high-dose intravenous immunoglobulins","volume":"28","author":"Terheyden","year":"2003","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.intimp.2005.11.017_bib51","series-title":"Intravenous immunoglobulin in dermatology","first-page":"93","article-title":"Scleromyxedema","author":"Jolles","year":"2003"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576905003139?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576905003139?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T04:04:17Z","timestamp":1554955457000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576905003139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,4]]}},"alternative-id":["S1567576905003139"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2005.11.017","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2006,4]]}}}